Compare Incyte Corporation (INCY) vs Lockheed Martin Corporation (LMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Lockheed Martin Corporation — how do they compare? Incyte Corporation trades at $121.47 (market cap $24.54B), while Lockheed Martin Corporation trades at $598.97 (market cap $137.96B). The key difference: Lockheed Martin Corporation is far larger — about 5.6× Incyte Corporation's market cap, and Lockheed Martin Corporation pays a 2.31% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | LMT | |
|---|---|---|
Market Cap | $24.54B | $137.96B |
Sector | Health | Industrials |
52-Week High | $129.93 | $676.70 |
52-Week Low | $81.61 | $431.56 |
Enterprise Value | $20.04B | $154.71B |
Dividend Yield | — | 2.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $121.55, near its consensus price target of $122.82, with a bullish technical signal and strong recent earnings beats. Revenue grew to $5.14B in 2025, with net income surging to $1.29B, reflecting robust profitability. The company raised its 2026 revenue outlook following strong Q2 results and positive developments like EU approval for Opzelura.
Outlook is positive with solid fundamentals and analyst support, though risks include competitive pressures and reliance on key products. The stock offers growth potential but requires monitoring of execution and market conditions.
Lockheed Martin (LMT) trades at $603.16, up 2.59% with strong technical momentum and bullish moving averages. The company reported mixed Q2 2026 earnings with a beat on EPS but faces margin pressure with net income margin declining to 8.16%. Recent news highlights major defense contracts including a $53.9 billion Patriot missile order and successful testing of next-generation interceptors, supporting the record $230 billion backlog.
Outlook remains positive with analyst consensus at Buy (56.76%) and $608 price target, though risks include execution on massive backlog and margin sustainability. The stock offers steady dividends ($3.45 quarterly) and benefits from elevated defense spending, but valuation multiples (P/E 22.04) require continued earnings growth to justify upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Lockheed Martin Corporation
Lockheed Martin is the largest defense contractor globally and has dominated the Western market for high-end fighter aircraft since the F-35 program was awarded in 2001. Lockheed's largest segment is aeronautics, which is dominated by the massive F-35 program. Lockheed's remaining segments are rotary and mission systems, which is mainly the Sikorsky helicopter business.
Read more on LMT →
